SELLAS Receives Fast Track designation from FDA for Galinpepimut-S for treatment of MM
SELLAS Life Sciences announced the FDA has granted Fast Track designation to the Company’s lead asset, galinpepimut-S (GPS), for treatment of multiple myeloma. GPS is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1protein. July 20, 2018